The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

ESMO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim ...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast can...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-ne...

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )

A new era of early cancer detection with blood test may change cancer screening ...

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )

New era of early cancer detection blood tests on the horizon

Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA

New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, US...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine t...

Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Net...

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy ( Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands )

Prognostic model of all-cause mortality at 30 days in patients with cancer and C...

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

Metastatic breast cancer endpoints for survival: rwPFS and TTNT ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer